Effects of intervention levels of natriuretic peptide on short-term prognosis of cardiogenic stroke

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100047408

Enrollment

Unknown

Registered

2021-06-18

Start date

2021-06-18

Completion date

Unknown

Last updated

2022-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiogenic stroke

Interventions

Experiment group:Recombinant human natriuretic peptide was administered

Control group:Routine medical treatment

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Skull magnetic resonance imaging (MRI) scan, CT, cardiac color ultrasound, ELECTROcardiogram, Holter, BNP and other examinations were performed, which met the requirements for clinical diagnosis of ischemic stroke combined with atrial fibrillation in the 2019 edition of Guidelines for the Prevention and Treatment of Cardiogenic Stroke in China (2019); 2.Acute decompensated heart failure with NT-proBNP >= 400 pg/ mL and dyspnea.

Exclusion criteria

Exclusion criteria: 1.Aged < 18 years; 2.End-stage renal disease or long-term maintenance dialysis; 3.Length of stay < 2 days; 4.Patients who are allergic to any of the components of the lyophilized recombinant human natriuretic peptide; 5.The medical history is incomplete; 6.Blood pressure systolic pressure below 90mmHg (1mmHg= 0.133kPa).

Design outcomes

Primary

Measure	Time frame
Serum protein concentrations of Furin, Corin, and PCSK6;	—

Countries

China

Contacts

Public ContactShen Xiaozhu

The Second People's Hospital of Lianyungang

499062796@qq.com+86 15895783306

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026